SUSTAINED VIRAL RESPONSE AND SAFETY OF MK-7009 IN CIRRHOTIC TREATMENT-EXPERIENCED PATIENTS WITH GENOTYPE 1 HCV INFECTION WHO HAVE FAILED PREVIOUS PEGYLATED INTERFERON AND RIBAVIRIN TREATMENT

被引：1
|
作者：
Rodriguez-Torres, M. [1 ]
Stoehr, A. [2 ]
Gane, E. [3 ]
Serfaty, L. [4 ]
Lawitz, E. [5 ]
Bourque, M. [6 ,7 ]
Bhanja, S. [6 ,7 ]
Barnard, R. [6 ,7 ]
Hwang, P. [6 ,7 ]
Mobashery, N. [6 ,7 ]
机构：
[1] Fdn Invest Diego, San Juan, PR USA
[2] IFI Inst Interdisziplinare Med, Hamburg, Germany
[3] Auckland Clin Studies Ltd, Auckland, New Zealand
[4] Univ Paris 06, Serv Hepatol, Paris, France
[5] Alamo Med Res, San Antonio, TX USA
[6] Merck Sharp & Dohme Corp, West Point, PA USA
[7] Merck Sharp & Dohme Corp, N Wales, PA USA
来源：
JOURNAL OF HEPATOLOGY | 2013年 / 58卷
关键词：
D O I：
10.1016/S0168-8278(13)60108-7
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
106
引用
收藏
页码：S47 / S47
页数：1
相关论文
共 50 条
  • [31] The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan
    Tsugiko Oze
    Naoki Hiramatsu
    Takayuki Yakushijin
    Kiyoshi Mochizuki
    Kazuho Imanaka
    Akira Yamada
    Masahide Oshita
    Akira Kaneko
    Hideki Hagiwara
    Eiji Mita
    Toshifumi Ito
    Toshihiko Nagase
    Yoshiaki Inui
    Taizo Hijioka
    Shinji Tamura
    Harumasa Yoshihara
    Eijiro Hayashi
    Yasuharu Imai
    Michio Kato
    Atsushi Hosui
    Takuya Miyagi
    Yuichi Yoshida
    Hisashi Ishida
    Tomohide Tatsumi
    Shinichi Kiso
    Tatsuya Kanto
    Akinori Kasahara
    Tetsuo Takehara
    Norio Hayashi
    Journal of Gastroenterology, 2011, 46 : 944 - 952
  • [32] Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial
    Zeuzem, Stefan
    Berg, Thomas
    Gane, Edward
    Ferenci, Peter
    Foster, Graham R.
    Fried, Michael W.
    Hezode, Christophe
    Hirschfield, Gideon M.
    Jacobson, Ira
    Nikitin, Igor
    Pockros, Paul J.
    Poordad, Fred
    Scott, Jane
    Lenz, Oliver
    Peeters, Monika
    Sekar, Vanitha
    De Smedt, Goedele
    Sinha, Rekha
    Beumont-Mauviel, Maria
    GASTROENTEROLOGY, 2014, 146 (02) : 430 - +
  • [33] ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection
    Andreone, Pietro
    Colombo, Massimo G.
    Enejosa, Jeffrey V.
    Koksal, Iftihar
    Ferenci, Peter
    Maieron, Andreas
    Muellhaupt, Beat
    Horsmans, Yves
    Weiland, Ola
    Reesink, Henk W.
    Rodrigues, Lino, Jr.
    Hu, Yiran B.
    Podsadecki, Thomas
    Bernstein, Barry
    GASTROENTEROLOGY, 2014, 147 (02) : 359 - +
  • [34] Treatment with pegylated interferon alpha 2B and ribavirin produces significant sustained virologic response rates in HCV infected patients who failed prior therapy
    Gaglio, PJ
    Brown, M
    Zimmerman, D
    Choi, J
    Heiler, L
    Brown, R
    GASTROENTEROLOGY, 2003, 124 (04) : A767 - A767
  • [35] Combination of Vaniprevir With Peginterferon and Ribavirin Significantly Increases the Rate of SVR in Treatment-Experienced Patients With Chronic HCV Genotype 1 Infection and Cirrhosis
    Rodriguez-Torres, Maribel
    Stoehr, Albrecht
    Gane, Edward J.
    Serfaty, Lawrence
    Lawitz, Eric
    Zhou, Amy
    Bourque, Michael
    Bhanja, Sanhita
    Strizki, Julie
    Barnard, Richard J. O.
    Hwang, Peggy M. T.
    DiNubile, Mark J.
    Mobashery, Niloufar
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2014, 12 (06) : 1029 - +
  • [36] Efficacy and Safety of Ombitasvir plus Paritaprevir, Ritonavir and Ribavirin in Non-cirrhotic Treatment-naïve and Treatment-experienced Egyptians with Chronic HCV Genotype-4 Infection
    Manar Ahmed
    Azza E. Mansey
    Engy A. Wahsh
    Ahmed A. Gomaa
    Hoda M. Rabea
    Current Medical Science, 2021, 41 : 581 - 586
  • [37] Early viral response and on treatment response to CPG 10101 (actilont™), in combination with pegylated interferon and/or ribavirin, in chronic HCV genotype 1 infected patients with prior relapse response
    Jacobson, Ira M.
    Ghalib, Reem
    Lawitz, Eric
    Freilich, Bradley
    Gordon, Stuart C.
    Kwo, Paul
    Riley, Thomas R.
    Bright, Diane
    Morriss, Mary L.
    Al-Adhami, Mohammed
    Himes, Julie L.
    Massari, Ferdinand E.
    McHutchison, John G.
    HEPATOLOGY, 2006, 44 (04) : 224A - 225A
  • [38] Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis
    Lim, Joseph K.
    Liapakis, Ann Marie
    Shiffman, Mitchell L.
    Lok, Anna S.
    Zeuzem, Stefan
    Terrault, Norah A.
    Park, James S.
    Landis, Charles S.
    Hassan, Mohamed
    Gallant, Joel
    Kuo, Alexander
    Pockros, Paul J.
    Vainorius, Monika
    Akushevich, Lucy
    Michael, Larry
    Fried, Michael W.
    Nelson, David R.
    Ben-Ari, Ziv
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2018, 16 (11) : 1811 - +
  • [39] Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients
    Dong Ji
    Guo-Feng Chen
    Cheng Wang
    Yu-Dong Wang
    Qing Shao
    Bing Li
    Jun Zhao
    Shao-Li You
    Jin-Hua Hu
    Jia-Liang Liu
    Xiao-Xia Niu
    Jing Chen
    Lei Lu
    Vanessa Wu
    George Lau
    Hepatology International, 2016, 10 : 789 - 798
  • [40] Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients
    Ji, Dong
    Chen, Guo-Feng
    Wang, Cheng
    Wang, Yu-Dong
    Shao, Qing
    Li, Bing
    Zhao, Jun
    You, Shao-Li
    Hu, Jin-a
    Liu, Jia-Liang
    Niu, Xiao-Xia
    Chen, Jing
    Lu, Lei
    Wu, Vanessa
    Lau, George
    HEPATOLOGY INTERNATIONAL, 2016, 10 (05) : 789 - 798
12345